Immunocore Holdings plc filed a Form 8-K with the SEC on September 14, 2026, disclosing that its Phase 3 TEBE-AM clinical trial has achieved target patient enrollment.

Key Highlights

  • Enrollment milestone reached: Immunocore announced the achievement of target patient enrollment in its Phase 3 TEBE-AM clinical trial.
  • Drug and combinations under study: The trial evaluates tebentafusp as monotherapy and in combination with pembrolizumab.
  • Target patient population: The trial focuses on HLA-A*02:01-positive patients with unresectable or metastatic melanoma whose disease has progressed following prior therapy.
  • Disclosure method: The announcement was made via a press release dated September 14, 2026, furnished as Exhibit 99.1 under Regulation FD.
  • Signed by: The filing was signed by Bahija Jallal, Ph.D., Chief Executive Officer of Immunocore Holdings plc.

Immunocore Reports Target Enrollment Achieved in TEBE-AM Melanoma Trial

According to the filing, Immunocore Holdings plc (NASDAQ:IMCR) issued a press release on September 14, 2026, announcing that the Phase 3 TEBE-AM clinical trial has reached its target patient enrollment. The trial is evaluating tebentafusp both as a monotherapy and in combination with pembrolizumab, according to the disclosure.

The filing specifies that the TEBE-AM trial is designed for HLA-A*02:01-positive patients diagnosed with unresectable or metastatic melanoma whose disease has progressed following prior therapy. The disclosure was made under Item 7.01, Regulation FD, meaning the information is furnished and, as the filing states, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended," and is not subject to the liabilities of that section.

The company noted that the press release, attached as Exhibit 99.1, is incorporated by reference into the Current Report. The filing was signed by Chief Executive Officer Bahija Jallal, Ph.D., on behalf of Immunocore Holdings plc, a company incorporated in England and Wales with its principal offices located at 92 Park Drive, Milton Park Abingdon, Oxfordshire, United Kingdom.

What Was Disclosed

Immunocore Holdings plc reported via an 8-K filed September 14, 2026, that target patient enrollment has been achieved in the Phase 3 TEBE-AM trial evaluating tebentafusp, as monotherapy and combined with pembrolizumab, in a specific melanoma patient population.